Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($0.20), $0.14 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $1.23 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.